Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
An. bras. dermatol
;
95(2): 221-237, Mar.-Apr. 2020. tab, graf
Article
in English
| LILACS, ColecionaSUS
| ID: biblio-1130848
ABSTRACT
Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Skin Diseases
/
Drug-Related Side Effects and Adverse Reactions
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Etiology study
/
Practice guideline
/
Risk factors
Limits:
Humans
Language:
English
Journal:
An. bras. dermatol
Year:
2020
Type:
Article
Institution/Affiliation country:
Centro Paulista de Oncologia/BR
/
Hospital Beneficência Portuguesa de São Paulo/BR
/
Hospital Sírio-Libanês/BR
/
Santa Casa de Misericórdia de São Paulo/BR
/
Universidade de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS